Aardvark Therapeutics posts Q2 2025 results update

Aardvark Therapeutics, Inc. reported that it issued a press release on August 13, 2025 detailing its financial results for the second quarter ended June 30, 2025, along with updates on its drug development pipeline and overall business.

Rhea-AI Filing Summary

Aardvark Therapeutics, Inc. reported that it issued a press release on August 13, 2025 detailing its financial results for the second quarter ended June 30, 2025, along with updates on its drug development pipeline and overall business. The press release is provided as Exhibit 99.1 and gives the full results and operational commentary.

The company specifies that this press release and related information are being furnished rather than filed, meaning they are not subject to certain legal liabilities under the Securities Exchange Act and are not automatically incorporated into other securities law documents unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aardvark Therapeutics (AARD) announce on August 13, 2025?

On August 13, 2025, Aardvark Therapeutics issued a press release reporting its financial results for the second quarter ended June 30, 2025 and providing pipeline and business updates.

Which period do the latest Aardvark Therapeutics (AARD) results cover?

The reported financial results from Aardvark Therapeutics cover the second quarter ended June 30, 2025.

Where can investors find the full Q2 2025 results for Aardvark Therapeutics (AARD)?

The full Q2 2025 results and commentary from Aardvark Therapeutics are contained in the press release furnished as Exhibit 99.1.

Is the Aardvark Therapeutics (AARD) Q2 2025 press release considered filed with the SEC?

The company states that the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Does the Aardvark Therapeutics (AARD) update include pipeline information?

Yes, the press release issued by Aardvark Therapeutics includes both financial results for Q2 2025 and pipeline and business updates.

Who signed the latest Aardvark Therapeutics (AARD) report?

The report was signed on behalf of Aardvark Therapeutics, Inc. by Tien-Li Lee, M.D., the company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/13/2025 - 04:34 PM Learn about SEC filing dates

0001774857false00017748572025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Aardvark Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42513	82-1606367
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4370 La Jolla Village Drive, Suite 1050
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 225-7696

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		AARD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the second quarter ended June 30, 2025, and providing pipeline and business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AARDVARK THERAPEUTICS, INC.
Date:	August 13, 2025	By:	/s/ Tien-Li Lee, M.D.
			Tien-Li Lee, M.D. Chief Executive Officer